Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients

Bone Marrow Transplantation

Volumn 22, Issue 6, 1998, Pages 575-577

  Narvios, A B ^a   Przepiorka, D ^a   Tarrand, J ^a   Chan, K W ^a   Champlin, R ^a   Lichtiger, B ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Cytomegalovirus infections; Filtered blood components

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FILTER; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS CULTURE; VIRUS TRANSMISSION;

EID: 0031692510     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701361     Document Type: Article

References (12)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Bow den RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. New Engl J Med 1986; 314: 1006-1010.
3. Miller WJ, McCullough J, Balfour HH et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227-234.
4. Verdonck LF, de Graan-Hentzen YCE, Dekker AW et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary CMV infection after bone marrow transplant. Bone Marrow Transplant 1987; 2: 73-78.
5. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infections after marrow transplant. Blood 1991; 78: 246-250.
6. Bowden RA, Slichter SJ, Sayers MH et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
7. Narvios AB, Alvarez FE, Glassman A, Lichtiger B. Assessing the efficiency of leukoreduction of cellular blood components. Use of a simplified formalin-fixation and batch-counting method. Am J Clin Pathol 1997; 107: 111-113.
8. Wingard JR, Chen DY-H, Burns WH et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432-1437.
9. van Prooijen HC, Visser JJ, van Oostendorp WR et al. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87: 144-147.
10. Przepiorka D, LeParc GF, Werch J, Lichtiger B. Prevention of transfusion-associated cytomegalovirus infection. Practice parameter. Am J Clin Pathol 1996; 106: 163-169.
11. Wilhelm JA, Matter L, Schopper K. The risk of transmitting cytomegalovirus to patients receiving blood transfusion. J Infect Dis 1986; 154: 169-171.
12. Murphy MF, Grint PC, Hardiman AE et al. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia. Br J Haematol 1988; 70: 253-255.